阿利西尤单抗联合参芎葡萄糖注射液对急性非ST段抬高型心肌梗死PCI患者冠状动脉微循环、心血管结局的影响
于瑞苏 , 马喆恒
中国现代医学杂志 ›› 2026, Vol. 36 ›› Issue (17) : 1 -7.
阿利西尤单抗联合参芎葡萄糖注射液对急性非ST段抬高型心肌梗死PCI患者冠状动脉微循环、心血管结局的影响
Effects of alirocumab combined with Shenxiong Glucose Injection on coronary microcirculation and cardiovascular outcomes in PCI patients with acute non-ST‑elevation myocardial infarction
目的 观察急性非ST段抬高型心肌梗死(NSTEMI)经皮冠状动脉介入术(PCI)患者治疗中阿利西尤单抗联合参芎葡萄糖注射液的效果。 方法 选取2023年5月—2024年2月徐州市中心医院行PCI的NSTEMI患者78例,通过区组随机化分为对照组、试验组。对照组PCI后采用阿利西尤单抗治疗,试验组在对照组基础上使用参芎葡萄糖注射液。两组均于治疗1个月后观察疗效。比较两组心功能、冠状动脉微循环指标、心肌呈色分级(MBG)、主要不良心血管事件(MACE)及不良反应。 结果 PCI后1个月试验组左心房内径(LAD)、左心房容积(LAV)、左心室舒张末期内径(LVDd)均低于对照组,试验组左心室射血分数(LVEF)、二尖瓣血流频谱E/A比值(E/A)均高于对照组(P <0.05)。PCI后1个月与PCI后即刻,对照组LAD、LAV、LVEF、LVDd及E/A的差值均低于试验组(均P <0.05)。PCI后1个月试验组心肌微循环阻力指数(IMR)低于对照组,试验组冠状动脉血流储备(CFR)、瞬时无波形比值(iFR)均高于对照组(P <0.05);PCI后1个月与PCI后即刻,对照组CFR、IMR、iFR差值均低于试验组(P <0.05)。两组术后MBG比较,试验组MBG 3级占比高于对照组(P <0.05)。两组手术前后MBG比较,术后MBG 2、3级占比高于术前(P <0.05)。试验组MACE总发生率低于对照组(P <0.05)。试验组与对照组不良反应总发生率比较,差异无统计学意义(P >0.05)。 结论 阿利西尤单抗联合参芎葡萄糖注射液可改善NSTEMI患者PCI后心功能、冠状动脉微循环及心血管结局,且不增加药物不良反应。
Objective To observe the efficacy of alirocumab combined with Shenxiong Glucose Injection in the treatment of patients with acute non‑ST‑elevation myocardial infarction (NSTEMI) undergoing percutaneous coronary intervention (PCI). Methods A total of 78 NSTEMI patients undergoing PCI were randomly divided into a control group and a trial group using block randomization. The control group received alirocumab after PCI, and the trial group received additional Shenxiong Glucose Injection on the basis of the control group. The therapeutic efficacy was evaluated 1 month after treatment in both groups. Cardiac function, coronary microcirculation indexes, myocardial blush grade (MBG), major adverse cardiovascular events (MACE), and adverse reactions were compared between the two groups. Results At 1 month after PCI, there were significant differences in left atrial diameter (LAD), left atrial volume (LAV), left ventricular ejection fraction (LVEF), left ventricular end‑diastolic diameter (LVDd), and mitral inflow E/A ratio (E/A) between the control group and the trial group (P < 0.05). LAD, LAV, and LVDd were lower, while LVEF and E/A were higher in the trial group than in the control group. The changes in LAD, LAV, LVEF, LVDd, and E/A from immediately after PCI to 1 month after PCI were significantly different between the two groups (P < 0.05). The changes in LAD, LAV, LVEF, LVDd, and E/A were smaller in the control group than in the trial group. At 1 month after PCI, there were significant differences in coronary flow reserve (CFR), index of microcirculatory resistance (IMR), and instantaneous wave‑free ratio (iFR) between the two groups (P < 0.05). IMR was lower, while CFR and iFR were higher in the trial group than in the control group. The changes in CFR, IMR, and iFR from immediately after PCI to 1 month after PCI were significantly different between the two groups (P < 0.05). The changes in CFR, IMR, and iFR in the control group were smaller than those in the trial group. There was a significant difference in postoperative MBG between the two groups (P < 0.05), with a higher MBG in the trial group. MBG was significantly improved after surgery in both the control group and the trial group (P < 0.05). The total incidence of MACE was significantly lower in the trial group than in the control group (P < 0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P > 0.05). Conclusion Alirocumab combined with Shenxiong Glucose Injection can improve cardiac function, coronary microcirculation, and cardiovascular outcomes in NSTEMI patients after PCI without increasing adverse drug reactions.
| [1] |
Bergmark B A, Mathenge N, Merlini P A, et al. Acute coronary syndromes[J]. Lancet, 2022, 399(10332): 1347-1358. |
| [2] |
崔少华, 耿晓玲, 杨晓玮. 右美托咪定联合舒芬太尼对急性心肌梗死患者经皮冠状动脉介入治疗术后疼痛和心肌酶谱的影响[J]. 中国临床药理学杂志, 2023, 39(24): 3556-3560. |
| [3] |
孙莹莹, 常丽辉, 苗文霞, 急性NSTEMI患者PCI术后血清FAR、γ-GGT、NT-proBNP水平及对预后的预测价值研究[J]. 临床和实验医学杂志, 2024, 23(15): 1576-1580. |
| [4] |
Hagström E, Steg P G, Szarek M, et al. Apolipoprotein B, residual cardiovascular risk after acute coronary syndrome, and effects of alirocumab[J]. Circulation, 2022, 146(9): 657-672. |
| [5] |
魏傲, 李强, 丁玲, 参芎注射液对急性非ST段抬高型心肌梗死患者外周血Th17及Treg细胞亚群的影响[J]. 西部中医药, 2022, 35(6): 107-110. |
| [6] |
Mair J, Jaffe A, Lindahl B, et al. The clinical approach to diagnosing peri-procedural myocardial infarction after percutaneous coronary interventions according to the fourth universal definition of myocardial infarction - from the study group on biomarkers of the European Society of Cardiology (ESC) Association for Acute CardioVascular Care (ACVC)[J]. Biomarkers, 2022, 27(5): 407-417. |
| [7] |
Greco C, Pelliccia F, Tanzilli G, et al. Usefulness of local delivery of thrombolytics before thrombectomy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention (the delivery of thrombolytics before thrombectomy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention [DISSOLUTION] randomized trial)[J]. Am J Cardiol, 2013, 112(5): 630-635. |
| [8] |
Räber L, Ueki Y, Otsuka T, et al. Effect of alirocumab added to High-Intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial[J]. JAMA, 2022, 327(18): 1771-1781. |
| [9] |
Benenati S, Montorfano M, Pica S, et al. Coronary physiology thresholds associated with microvascular obstruction in myocardial infarction[J]. Heart, 2024, 110(4): 271-280. |
| [10] |
Demirkiran A, Van Der Hoeven N W, Janssens G N, et al. Left ventricular function, strain, and infarct characteristics in patients with transient ST-segment elevation myocardial infarction compared to ST-segment and non-ST-segment elevation myocardial infarctions[J]. Eur Heart J Cardiovasc Imaging, 2022, 23(6): 836-845. |
| [11] |
Zhou L P, Hu X M, Zhang H T, et al. Effects of atorvastatin and rosuvastatin on dysfunctional coronary circulation in patients with ST-segment elevation myocardial infarction[J]. J Int Med Res, 2023, 51(6): 3000605231182547. |
| [12] |
Spadafora L, Pastena P, Cacciatore S, et al. One-year prognostic differences and management strategies between ST-elevation and non-ST-elevation myocardial infarction: insights from the PRAISE registry[J]. Am J Cardiovasc Drugs, 2025, 25(5): 681-691. |
| [13] |
Ortona S, Barisione C, Ferrari P F, et al. PCSK9 and other metabolic targets to counteract ischemia/reperfusion injury in acute myocardial infarction and visceral vascular surgery[J]. J Clin Med, 2022, 11(13): 3638. |
| [14] |
俞佳, 蒋科, 郭莹. 阿利西尤单抗联合阿托伐他汀间歇治疗老年他汀不耐受脑梗死合并高脂血症患者的疗效分析[J]. 中国现代医学杂志, 2024, 34(14): 66-70. |
| [15] |
Atia A, Aboeldahab H, Wageeh A, et al. Safety and efficacy of proprotein convertase Subtilisin-Kexin type 9 inhibitors after acute coronary syndrome: a meta-analysis of randomized controlled trials[J]. Am J Cardiovasc Drugs, 2024, 24(1): 83-102. |
| [16] |
石俊婷, 吴晓洁, 靳净, 阿利西尤单抗对急性冠状动脉综合征患者经皮冠状动脉介入术中慢血流或无复流的影响[J]. 血管与腔内血管外科杂志, 2025, 11(3): 392-398. |
| [17] |
陆秋平, 贺露霄, 罗叶, 依洛尤单抗和阿利西尤单抗治疗急性冠状动脉综合征的网状meta分析[J]. 中国现代应用药学, 2025, 42(13): 2287-2296. |
| [18] |
Toth P P, Bray S, Villa G, et al. Network meta-analysis of randomized trials evaluating the comparative efficacy of lipid-lowering therapies added to maximally tolerated statins for the reduction of low-density lipoprotein cholesterol[J]. J Am Heart Assoc, 2022, 11(18): e025551. |
| [19] |
陆定艳, 吴忠秀, 孙佳, 基于蛋白质组学分析参芎葡萄糖注射液拮抗H2O2诱导H9c2细胞氧化损伤的作用机制[J]. 中国实验方剂学杂志, 2022, 28(1): 141-149. |
| [20] |
张静雅, 刘利琴, 李容, 参芎葡萄糖注射液在正常和急性心肌缺血大鼠体内的药动学差异[J]. 中国药房, 2022, 33(4): 433-438. |
| [21] |
张艳军, 王晓丽, 董萌, 阿利西尤单抗联合依折麦布治疗老年急性脑梗死合并高脂血症的效果研究[J]. 中国现代医学杂志, 2025, 35(8): 50-54. |
| [22] |
Wang X, Guo Q, Guo R F, et al. Coronary angiography-derived index of microcirculatory resistance and evolution of infarct pathology after ST-segment-elevation myocardial infarction[J]. Eur Heart J Cardiovasc Imaging, 2023, 24(12): 1640-1652. |
| [23] |
刘欢, 吴忠秀, 陆定艳, 参芎葡萄糖注射液对CoCl2诱导的H9c2细胞凋亡的影响[J]. 中成药, 2021, 43(5): 1152-1157. |
| [24] |
郝翠君, 王蕊, 马逸平, 阿利西尤单抗联合阿托伐他汀对急性冠脉综合征患者PCI术后临床疗效和安全性的影响[J]. 中国药房, 2025, 36(10): 1216-1220. |
| [25] |
杨洋, 杨红玉, 杨月明, 参芎葡萄糖注射液安全性风险分析与思考[J]. 安徽医药, 2023, 27(5): 1057-1060. |
江苏省自然科学基金(BK20241720)
/
| 〈 |
|
〉 |